Published in final edited form as:

Int J Pharm. 2007 July 18; 339(1-2): 139–147. doi:10.1016/j.ijpharm.2007.02.036.

Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor

Sheetal Agarwal, Dhananjay Pal, and Ashim K. Mitra*

Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, 5005 Rockhill Road, Kansas city, MO 64110-2499, USA

Abstract

Polarized epithelial non-human (canine) cell lines stably transfected with human or murine complementary DNA (cDNA) encoding for various efflux transporters (P-gp/MDR1, MRP1, MRP2, and Bcrp1) were used to study transepithelial transport of Lopinavir (LVR) and compare results with the MDCKII-Wild type cells. These transmembrane proteins cause multidrug resistance by decreasing the total intracellular accumulation of drugs. Lopinavir efflux was directional and was completely inhibited by MK-571, a selective MRP family inhibitor in the MDCKII-MRP2 cell line. Similarly, LVR efflux was also inhibited by P-gp inhibitors P-gp 4008 and GF120918 in the MDCKII-MDR1 cell line. The efflux ratios (Efflux rate/ Influx rate) of LVR in the absence of any efflux inhibitors in the MDCK-Wild type, MDCKII-MDR1, MDCKII-MRP1 and MDCKII-MRP2 cell monolayers were 1.32, 4.91, 1.26 and 2.89 respectively. The MDCKII-MDR1 and MDCKII-MRP2 cells have significantly increased LVR efflux ratio relative to the parental cells due to the apically directed transport by MDR1 and MRP2 respectively. The efflux ratios in MRP2 and MDR1 transfected cell lines were close to unity in the presence of MK-571 and P-gp 4008 respectively; indicating that LVR efflux by MRP2 and P-gp was completely inhibited by their selective inhibitors. MDCKII-MRP1 cells did not exhibit a significant reduction in the LVR efflux relative to the parental cells, indicating that LVR is not a good substrate for MRP1. Transport studies across MDCKII-Bcrp1 cells indicated that LVR is not transported by Bcrp1 and is not a substrate for this efflux protein. In conclusion, this study presents direct evidence that LVR is effluxed by both P-gp and MRP2 which may contribute to its poor oral bioavailability and limited penetration into the CNS.

Keywords

MDCKII-MDR1; MDCKII-MRP2; MDCKII-MRP1; MDCKII-Bcrp1; MDCKII-WT; P-glycoprotein (P-gp); multidrug resistance protein (MRP); breast cancer resistance protein (BCRP); Lopinavir (LVR); uptake; transport; permeability; efflux ratio (ER)

© 2007 Elsevier B.V. All rights reserved.

*Corresponding Author: Ashim K. Mitra, Ph.D., University of Missouri Curators' Professor of Pharmacy, Chairman, Pharmaceutical Sciences, Vice-Provost for Interdisciplinary Research, University of Missouri - Kansas City, Phone: 816-235-1615, Fax: 816-235-5190, mitraa@umkc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. INTRODUCTION

HIV protease inhibitors (PIs) have revolutionized the treatment of HIV infection (Roberts et al., 1990; Vacca et al., 1994; Danner et al., 1995; Kempf et al., 1995; Patick et al., 1996). Due to limited oral bioavailability and poor pharmacokinetics of many of the currently available PIs, additional efforts have been made to design more potent PIs with improved pharmacokinetic properties. Lopinavir (LVR), an analog of ritonavir (RVR) is a potent inhibitor of wild type and mutant HIV protease ($K_i = 1.3\text{--}28\text{ pM}$) (Kumar et al., 2004). Its structure is outlined in Fig.1. The LVR: RVR combination (KALETRA) has been shown to be effective in the treatment of HIV infection and is approved for clinical use (Hurst and Faulds, 2000; Miller, 2000). LVR, as such, is extensively metabolized by CYP3A4 and produces low systemic availability when administered alone. RVR potentially inhibits CYP3A4 and is used in combination with LVR to enhance the systemic exposure of LVR (Kumar et al., 1999) This combination results in LVR concentrations that greatly exceed those necessary *in vitro* to inhibit both wild-type and PI-resistant HIV isolates. (Kaletra® Prescribing Information. Abbott Laboratories, January 2002).

The low oral bioavailability of LVR was attributed to high first-pass metabolism (Kumar et al., 2004). *In vitro* investigations with human liver microsomes have shown that cytochrome P450 3A plays a predominant role in the metabolism of LVR. High first pass metabolism can also occur due to intestinal efflux which can lead to increased exposure time to metabolizing enzymes (Wacher et al., 1995; Wacher et al., 2001; Katragadda et al., 2005). We have hypothesized that the low oral bioavailability of LVR and possibly limited brain penetration could be in part due to efflux of LVR by several efflux pumps such as P-glycoprotein (P-gp), multidrug-resistance related proteins (MRPs) and breast cancer resistance protein (BCRP) present on intestinal epithelial and blood capillary endothelial cells. Potential interaction between efflux transporters in the gut and CYP3A4 metabolizing enzymes may be a source of variation associated with LVR absorption and distribution (Williams and Sinko, 1999). In human, CYP3A4 is the principal enzyme involved in the hepatic and intestinal drug metabolism, and there is a striking overlap of substrate specificities among CYP3A4, P-gp and MRPs. The coordinated function of both CYP3A and P-gp, MRPs can dramatically lower oral bioavailability of compounds which are substrates for both (van Asperen et al., 1997; Wacher et al., 1998) and this may also be true for LVR.

P-gp mediated efflux of LVR has been published (Vishnuvardhan et al., 2003; Woodahl et al., 2005) but interactions of LVR with other adenosine triphosphate- binding cassette (ABC) efflux transporters such as MRPs and BCRP have not yet been investigated. Therefore, it is important to delineate quantitatively if these latter efflux transporters can restrict, at least in part, the permeation of LVR at both the intestinal and blood brain barrier (BBB) membranes.

ABC transporters comprise one of the largest membrane bound protein families. These proteins transport substrates against a concentration gradient with ATP hydrolysis as a driving force across the membrane. P-gp, a multiple drug resistant (MDR) gene product, transports a wide range of compounds, including anticancer drugs, steroids, calcium channel blockers and antihistamines (Endicott and Ling, 1989; Borst et al., 1993; Germann et al., 1993; Borst et al., 2000; Pal and Mitra, 2006). P-gp-mediated efflux reduces the intracellular accumulation of these compounds, thereby diminishing drug efficacy. P-gp is present on the apical membrane of many absorptive epithelial and endothelial cells. Because of its localization and distribution, P-gp limits the oral absorption and bioavailability of PIs across intestine, brain, testis and placenta (Kim et al., 1998; Polli et al., 1999; Smit et al., 1999; Choo et al., 2000; Huisman et al., 2001; Huisman et al., 2002).

Recent studies have demonstrated that the PIs are also substrates for the MRPs, belonging to the same ABC transporter family (Huisman et al., 2002; Bachmeier et al., 2005). So far, eight MRP homologs have been identified for ABC proteins, MRP1-8. MRP1 is a widely expressed transporter. When present in epithelial cells, this protein is found primarily in the basolateral membrane (Hipfner et al., 1999). However, it has been reported that MRP1 does not mediate substantial polarized transport of PIs in MDCKII-MRP1 cells (Huisman et al., 2002). In contrast to MRP1, MRP2 is localized on the apical membrane of several epithelia. Functionally it is similar to P-gp mediated elimination of toxic compounds in gut and placenta (Kruh and Belinsky, 2003). It has been fairly established that MRP2 effluxes PIs (Huisman et al., 2002; Williams et al., 2002).

Human BCRP/MXR is a relatively new ABC efflux transporter. Like P-gp, BCRP confers high levels of resistance to anthracyclines, mitoxantrone, and the camptothecins by enhancing drug efflux from the cell to extracellular space (Litman et al., 2000; Bates et al., 2001; Ejendal and Hrycyna, 2002). BCRP is expressed in larger amounts than P-gp in the intestine (Taipalensuu et al., 2001). The expression of a BCRP homologue, known as brain multidrug resistance protein (BMRP), has also been reported in porcine brain capillary endothelial cells (Eisenblatter et al., 2003). Both BCRP and BMRP possess one half of the MDR1 P-gp structure with only six transmembrane domains and one ATP binding domain (Doyle et al., 1998). In addition to this structural similarity, most known substrates for BCRP/BMRP are similar to P-gp (i.e., hydrophobic, amphiphilic xenobiotics), suggesting that PIs may also interact with BCRP/BMRP (Litman et al., 2001; Doyle and Ross, 2003). In fact, results from a recent study suggest that SQV, RVR and nelfinavir (NFV) may serve as inhibitors of BCRP (Gupta et al., 2004).

Thus, P-gp and MRPs, can play an important role in lowering intestinal absorption and brain penetration of LVR. Because these efflux transporters are oriented in the secretory (i.e., out of the organ or tissue) direction, high efflux will lead to lower net absorption for LVR. Sub-therapeutic concentrations of PIs in the sanctuary sites like brain, testes and bone-marrow may cause persistence of viral infections leading to drug resistance (Williams and Sinko, 1999). Therefore, the purpose of this study is to assess the affinity of LVR for the efflux transporters using a well-defined system consisting of polarized non-human (canine) MDCKII cells, singly transfected with human MDR1, human MRP1/MRP2 complementary DNA (cDNA) or murine Bcrp1 cDNA and also to delineate quantitatively whether efflux limits permeation of LVR across intestinal and BBB absorptive cells.

2. MATERIALS AND METHODS

2.1. MATERIALS

Unlabeled (ulb) LVR, Fumitremorgin-C (FC) and GF120918 (GF) were generous gifts from Abbott Laboratories Inc; National Institutes of Health AIDS Research and Reference Reagent Program (National Institutes of Health, Bethesda, MD) and GlaxoSmithKline Ltd respectively. [3H] LVR (1Ci/mmol) and [3H] Mitoxantrone (MX) (4Ci/mmol) were purchased from Moravek Biochemicals (Brea, CA, USA). P-gp 4008 (P4) and MK-571 (MK) were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Biomol (Plymouth meeting, PA, USA) respectively. High-performance liquid chromatography grade DMSO and methanol were obtained from Fisher Scientific Co. (Pittsburgh, PA, USA) and were used as solvents for preparing stock solutions of all drugs and inhibitors. Trypsin-EDTA solution, Dulbecco's modified Eagle's medium (DMEM), Ham's F-10 medium and Minimum Essential Medium (MEM) were obtained from Invitrogen (Carlsbad, CA, USA) and fetal bovine serum (FBS) was obtained from Atlanta biologicals (Lawrenceville, GA, USA) respectively. Transwell plates were procured from Corning Costar Corp (Cambridge,

MA, USA). All other chemicals were commercial products of reagent or enzymatic grade and were obtained from Fisher Scientific or Sigma Chemicals.

2.2. METHODS

2.2.1. CELL CULTURE—Studies were performed with wild-type Madin-Darby canine kidney cells type II (MDCKII-WT, a well-characterized, polarized epithelial cell line) and stable MDCKII transfectants overexpressing hMRP1 (MDCKII-MRP1 cells), hMRP2 (MDCKII-MRP2 cells), hP-gp/MDR1 (MDCKII-MDR1 cells) and murine Bcrp1 (MDCKII-Bcrp1 cells) (generously provided by Drs. A. Schinkel and P. Borst, The Netherlands Cancer Institute, Amsterdam). These cell lines were selected as these were the first known polarized epithelial cells that stably express these transporters, enabling direct comparison of their functional behaviors without the confounding effects of multiple transporters expressed in cell lines such as Caco-2 (Evers et al., 1997; Evers et al., 1998; Kool et al., 1999; Evers et al., 2000; Jonker et al., 2000; Wijnholds et al., 2000). Studies were performed with the following cell passage numbers from our initial stock: MDCKII-WT (passages 30 to 40), MDCKII-MRP1 (passages 5 to 25), MDCKII-MRP2 (passages 5 to 25), MDCKII-MDR1 (passages 5 to 15) and MDCKII-Bcrp1 (passages 1–5). MDCKII cell lines were cultured in T-75 flasks with DMEM (with high glucose and glutamine concentrations) supplemented with 10% FBS, 1% nonessential amino acids, penicillin 100µg/ml and streptomycin 100µg/ml. The medium was changed every alternate day; cells were harvested and passaged via trypsinization at 80 to 90% confluence (about 4 days of growth). Cells were also grown on collagen coated Transwell inserts (12-mm) with transparent polyester membranes. Transwell inserts were coated with type 1 rat tail collagen (100µg/cm²), equilibrated with medium, and seeded at a density of 25,000cells/cm². Following seeding, medium was changed every alternate day, and transport or uptake studies were performed after 5–7 days.

2.2.2. TRANSPORT STUDIES—LVR transport was evaluated with monolayer of each cell line. All transport studies were performed with Dulbecco's modified phosphate-buffered saline (DPBS) containing glucose (1 g/liter) and HEPES (20mM) at pH 7.4. LVR and other drug solutions were prepared immediately prior to initiating a transport study. LVR was dissolved in methanol (not exceeding 2% v/v as the final concentration) and inhibitors were separately dissolved in DMSO (not exceeding 2% v/v as the final concentration) to prepare a stock solution and then diluted with DPBS to the specified working concentrations. Control solutions also contained the same amount of methanol/DMSO as in the drug solutions. Volumes of test solutions added were 0.5 and 1.5ml, for apical (A) and basolateral (B) chambers respectively. Prior to testing, cultured monolayers were rinsed and equilibrated for 30 min with DPBS. While the drug solution was added either in the donor (A or B) chambers, the receiving chamber contained only DPBS. Efflux inhibitors were added to both donor and acceptor solutions. Samples (100µl) were withdrawn from the receiving chamber at predetermined time points (30, 60, 90, 120, 150 and 180 min) and replaced with equal volume of DPBS to maintain sink conditions. Samples were transferred to scintillation vials containing 5ml of scintillation fluid, and radioactivity was analyzed using a Beckman Scintillation Counter (LS6500). All transport studies were performed at least in triplicates ($n=3$) per treatment group. Representative results are presented for each study.

2.2.3. DELINEATION OF SPECIFIC EFFLUX TRANSPORT—P-gp mediated transporter function was selectively inhibited with P-gp 4008 (P4), a specific inhibitor of P-gp (Lee et al., 2004). For specific experiments, GF120918 (GF), a specific inhibitor of P glycoprotein and BCRP only, was used to inhibit P-gp (Hyafil et al., 1993). GF is found to modulate cells expressing P-gp and BCRP (de Bruin et al., 1999; Wallstab et al., 1999). MRP family transporters were selectively inhibited with MK-571 (MK), a specific leukotriene D4 (LTD4) receptor antagonist. MK specifically inhibits at least MRP1 and

MRP2, but not P-gp. MK has been shown to sensitize MRP1- and MRP2-expressing cell lines (Gekeler et al., 1995; van Aubel et al., 1998; Chen et al., 1999). Specific BCRP efflux inhibitor Fumitremogin-C (FC) was used to inhibit Bcrp1 mediated transport (Shukla et al., 2006). A concentration dependent study was performed with increasing concentrations of inhibitors, MK in MDCKII-MRP2 cells, P4 and GF in MDCKII-MDR1 cells and FC in MDCKII-Bcrp1 cells, which demonstrated maximal inhibition at 100 μ M, 50 μ M and 2 μ M and 10 μ M respectively (Tables 3, 4 and 5). The viability of the cells was examined in our laboratory using the MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cell viability assay (Mosmann, 1983) at various inhibitory concentrations (0–250 μ M for MK 571, 0–50 μ M for Pgp-4008, 0–10 μ M for GF and 0–10 μ M for FC). No significant difference in viability was observed for control and treated cells (data not shown). To chemically inhibit MRPs in MDCKII-MRP transfected cell lines, the cell monolayer was equilibrated with MK (100 μ M in transport buffer) for 30 min prior to initiating an experiment to delineate the function of MRPs in LVR transport. Similarly, P4 (50 μ M) and FC (10 μ M) were added to inhibit P-gp and Bcrp1 in MDCKII-MDR1 and MDCKII-Bcrp1 cells respectively. The LVR (0.5 μ Ci/ml) solutions used in these transport studies also contained the respective inhibitors.

2.2.4. UPTAKE STUDIES

2.2.4.1. INHIBITION OF BCRP1-MEDIATED EFFLUX OF [3H]

MITOXANTRONE: Mitoxantrone (MX) is a fluorescent compound and a well known BCRP substrate. Direct efflux of [3H] MX in MDCKII-Bcrp1 cells in the presence and absence of unlabeled LVR was measured to examine whether LVR inhibits Bcrp1-mediated efflux of [3H] MX. Briefly, cells were incubated with [3H] LVR (0.5 μ Ci/ml) and various concentrations of unlabeled LVR (0–25 μ M) or FC (10 μ M), in 1 ml of incubation buffer (DPBS pH 7.4.) for 30 min at 37°C. Cells were then washed once with ice-cold PBS, and resuspended in 1ml of incubation buffer for 1 h at 37°C. Efflux was terminated by washing once in ice-cold PBS. The cell pellet was lysed with 1ml of 1% SDS and 500 μ l of the lysate was utilized for scintillation counting. Values were normalized to protein concentration that was measured using the remaining lysate by the modified Lowry assay. Intracellular [3H] MX was calculated based on the radioactivity associated with the cells and expressed as Pico moles of MX per mg of protein.

2.3. DATA ANALYSIS

Linear regression of the amounts transported as a function of time yielded the rate of transport across the cell monolayer (dM/dt). Rate divided by the cross-sectional area available for transport (Kempf et al.) generated the steady state flux as shown in Eq. 1.

$$\text{Flux} = (\text{dM}/\text{dt})/A \quad \text{Eq. 1}$$

Permeability was calculated by normalizing the steady state flux to the donor drug concentration (C_d) according to Eq. 2.

$$\text{Permeability} = \text{Flux}/C_d \quad \text{Eq. 2}$$

Efflux ratio (ER) was calculated by dividing the BL-AP permeability by AP-BL permeability as shown in Eq.3.

$$\text{Efflux ratio} = \text{BL} - \text{AP permeability} / \text{AP} - \text{BL permeability}$$

Eq. 3

2.4. STATISTICAL ANALYSIS

All experiments were conducted at least in triplicate ($n=3$) and results are expressed as mean $\pm$ SD. Statistical comparison of mean values were performed using one-way analysis of variance (ANOVA) or Student t test (Graph Pad INSTAT, version 3.1). $*P < 0.05$ was considered to be statistically significant.

3. RESULTS AND DISCUSSION

3.1. [3H] LVR transport across the MDCKII-WT cell line

[3H] LVR transport across the MDCKII-WT cells was determined in the absence and presence of various combinations of inhibitors. This study enabled us to compare the [3H] LVR permeabilities across the parental and the transfected cell lines in the absence and presence of specific efflux inhibitors. LVR permeabilities across MDCKII-WT cells are summarized in Table 1. Directional transport of [3H] LVR across MDCKII-WT cells in the absence of efflux inhibitors was very low (Fig. 2a). As a result, there was not a significant difference in the permeability of [3H] LVR in the absence or presence of P-gp, MRP and BCRP efflux inhibitors (Fig. 2b) in both A and B directions as compared to control, indicating minimal expressions of efflux transporters in MDCKII-WT cells. Efflux ratios of [3H] LVR in MDCKII-WT were 1.32 in the absence of any inhibitor and 1.10, 1.08, 1.27 and 1.07 in the presence of P-gp inhibitor (P4), MRP inhibitor (MK), BCRP inhibitor (FC) and all the three inhibitors combined (P4+FC+MK) respectively (Table 1). Therefore, it can be easily concluded from this study that a very minimal level of active efflux transporters is expressed in the MDCKII-WT cell line.

3.2. [3H] LVR transport across MDCKII-MDR1 cells

LVR permeabilities and the respective ERs obtained in the MDCKII-MDR1 transfected cell line are presented in Table 2. MDCKII-MDR1 cells exhibited significant directional transport of [3H] LVR in the B-A direction. LVR B-A transport was significantly higher (5 fold) as compared to A-B transport (Figs. 2c and 2d). A concentration dependent inhibition of LVR transport indicated that P4 at 50 μ M concentration was optimal for inhibition of P-gp mediated efflux in MDCKII-MDR1 cells. In the presence of P4, the AB and B-A transport of [3H] LVR was almost similar with an ER close to 1.03 as compared to 4.91 for the control. We further challenged LVR transport with another P-gp inhibitor, GF, which also inhibits BCRP in addition to P-gp. At 2 μ M concentration, GF exhibited an ER of 1.06 (a number similar to P4) thereby causing a complete blockade of LVR efflux.

3.3. [3H] LVR transport across MDCKII-MRP2 cells

LVR permeabilities and the respective ERs obtained in the MDCKII-MRP2 transfected cell line are presented in Table 3. MDCKII-MRP2 cells also exhibited significant directional transport of [3H] LVR. B-A transport of [3H] LVR was significantly higher (3 fold) relative to A-B transport (Figs. 2e and 2f). A concentration dependent inhibition of LVR transport indicated that 100 μ M MK produced complete inhibition of MRP mediated efflux. ER for [3H] LVR transport was found to be 2.9 in the absence of any inhibitor and 1.0 in the presence of MK, a MRP inhibitor. Therefore, MK at a concentration of 100 μ M was capable of completely blocking apically directed MRP2 mediated transport of [3H] LVR.

3.4. [3H] LVR transport across MDCKII-MRP1 cells

LVR permeabilities and respective ERs obtained in the MDCKII-MRP1 transfected cell line are noted in Table 4. MDCKII-MRP1 cells did not exhibit significant directional transport of [3H] LVR. ER for [3H] LVR transport was found to be 1.26 in the absence of any inhibitor, and 1.02 in the presence of 100 μ M MK. Although the difference in the ER values for LVR in the presence and absence of MK (0.24) are statistically significant, these values in MDCKII-MRP1 cells are not so significantly different for P-gp (3.88) and MRP2 (1.9) cell lines. These results indicate that LVR is not a good substrate for MRP1.

3.5. [3H] LVR transport across MDCKII-Bcrp1 cells

LVR permeabilities and respective ERs obtained in the MDCKII-Bcrp1 transfected cell line are summarized in Table 5. To determine the optimal concentration of FC for inhibition of Bcrp1 mediated efflux, a concentration dependent transport study was carried out with [3H] MX, a classic substrate for BCRP efflux pump. At 10 μ M FC concentration, MX exhibited an ER of 1.14 relative to 2.45 for control. Hence, this concentration was selected for all further inhibition experiments involving Bcrp1 mediated efflux. No significant directional transport of [3H] LVR was observed in MDCKII-Bcrp1 cell monolayer. ER values of [3H] LVR were 1.08 and 1.17 in the absence and in the presence of BCRP inhibitor respectively. These values are not significantly different suggesting that LVR is probably not transported by Bcrp1. Also, to confirm our observation that LVR is not a substrate for Bcrp1, cellular accumulation of [3H] MX was measured in MDCKII-Bcrp1 cells in the presence of unlabeled LVR and FC (Fig.3). Cellular uptake of MX was elevated in the presence of BCRP efflux inhibitor, but unlabeled LVR did not show any competitive uptake with MX. Therefore, this data substantiates our early conclusion that LVR is not a good substrate for Bcrp1.

3.6. Effects of multidrug resistance proteins on [3H] LVR transport

Effects of multidrug resistance proteins on [3H] LVR transport across all transfected MDCKII cell lines (MDCKII-MDR1, MDCKII-MRP2, MDCKII-MRP1 and MDCKII-Bcrp1) were compared with MDCKII-WT cell line (Tables 1–5). MDCK cells form a polarized monolayer in which the rate of basolaterally or apically directed translocation can be measured after adding compounds to the A or B side of the monolayer. Passive translocation will be similar in both directions. Since these efflux transporters excrete compounds from within the cell to extracellular space, the direction of transport will depend on the subcellular localization of such transporters in polarized cells. Thus MRP1, being localized on the basolateral membrane should transport in the B direction. Conversely MRP2, Bcrp1 and P-gp being localized on the apical membrane should transport in the apical direction. MDCKII-MDR1 and MDCKII-MRP2 cells exhibited significant directional transport of [3H] LVR in the B-A direction (Figs. 2c and 2e) as compared to MDCKII-WT cells (Fig.2a), indicating that these efflux transporters are present on the apical membrane. The differences in ER values of [3H] LVR transport across MDCKII-WT cells (1.32) relative to MDR1 (4.91) and MRP2 (2.89) transfected cell lines are highly significant. Such differences imply an increased efflux of [3H] LVR by MDR1 (P-gp) and MRP2 respectively due to enhanced expression of these transporters in these cell lines. The ER values in MDCKII-MDR1 and MDCKII-MRP2 cell lines were reduced to almost 1.0 in presence of efflux inhibitors, which suggest that LVR is a substrate for both P-gp and MRP2 efflux proteins. However, MRP1 and Bcrp1 did not produce substantial differences in directional transport of [3H] LVR as compared to MDCKII-WT cells, which confirms that LVR is not a good substrate for MRP1 and Bcrp1 efflux transporters.

Based on the results obtained in the above studies, specific inhibitors of P-gp and MRP2 significantly elevated the transport of LVR in the transfected cell lines, therefore there is no

doubt that these efflux transporters may not allow sufficient intracellular accumulation of LVR thereby reducing anti-HIV efficacy. Intestinal P-gp is localised extensively on the villus tip of enterocytes (Hunter et al., 1993)(i.e., the main site of absorption for orally administered compounds (Katragadda et al., 2005)). It is, therefore, ideally positioned to limit the absorption of compounds by pumping them back into lumen. Since, MRP2 is also now known to localize in the apical membrane of polarized cells, it is possible that MRP2 also play a synergistic role along with P-gp in the extrusion of LVR from the cells. Results presented in Tables 2 and 3 show that low concentrations of ulb LVR can inhibit MDR1 and MRP2 efflux activity. It has been reported earlier that PIs seem to be able to inhibit efflux proteins of *in vitro* cell models but with limited consequences *in vivo* (Gimenez et al., 2004). In the case of LVR, it undergoes extensive metabolism by CYP3A4 and its oral bioavailability in animal models by itself is very low. Also, it is practically insoluble in water. Moreover, individual transfected cell lines over express only one particular type of efflux transporter and have very limited expression of metabolizing enzyme (CYP3A4). But GIT expresses several efflux transporters and metabolizing enzymes over large surface areas, which together contribute to ultimate plasma concentration of a drug. The activity and expression of these efflux transporters in GIT will vary significantly when compared with *in vitro* conditions in transfected cell lines. Also, there is a report that after repeated administrations, most of the PIs are able to induce the expression and functionality of some efflux proteins (Gimenez et al., 2004). Therefore, even though low concentrations of LVR are required to inhibit efflux activity *in vitro*, its *in vivo* behavior cannot be postulated based on these results.

4. CONCLUSION

Our results demonstrate for the first time that LVR is extruded from absorptive cells by MRP2 and confirm that P-gp/MDR1 is involved in its efflux. This efflux can be prevented by specific inhibitors such as P4, GF120918 for P-gp and MK571 for MRP2. LVR did not interact significantly with MRP1. Also, no substantial difference was noted in the ER values of LVR in MDCKII-Bcrp1 cells in the presence and absence of FC, a specific and potent BCRP efflux inhibitor. This study clearly indicates that LVR is not a substrate of Bcrp1 and does not interact with Bcrp1. Thus, from these results it may be postulated that efflux transporters may limit oral absorption and brain permeation of LVR.

Acknowledgments

This work was supported by National Institute of Health Grant GM 64320-03

References

- Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. *Pharm Res.* 2005; 22:1259–1268. [PubMed: 16078135]
- Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in multidrug resistance. *J Bioenerg Biomembr.* 2001; 33:503–511. [PubMed: 11804192]
- Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. *J Natl Cancer Inst.* 2000; 92:1295–1302. [PubMed: 10944550]
- Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ, Eijdens EW, Baas F, Zaman GJ. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. *Pharmacol Ther.* 1993; 60:289–299. [PubMed: 7912835]
- Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. *Mol Pharmacol.* 1999; 56:1219–1228. [PubMed: 10570049]

- Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. *Drug Metab Dispos.* 2000; 28:655–660. [PubMed: 10820137]
- Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. *N Engl J Med.* 1995; 333:1528–1533. [PubMed: 7477167]
- de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. *Cancer Lett.* 1999; 146:117–126. [PubMed: 10656616]
- Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). *Oncogene.* 2003; 22:7340–7358. [PubMed: 14576842]
- Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc Natl Acad Sci U S A.* 1998; 95:15665–15670. [PubMed: 9861027]
- Eisenblatter T, Huwel S, Galla HJ. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. *Brain Res.* 2003; 971:221–231. [PubMed: 12706238]
- Ejendal KF, Hrycyna CA. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. *Curr Protein Pept Sci.* 2002; 3:503–511. [PubMed: 12369998]
- Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. *Annu Rev Biochem.* 1989; 58:137–171. [PubMed: 2570548]
- Evers R, Cnubben NH, Wijnholds J, van Deemter L, van Bladeren PJ, Borst P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. *FEBS Lett.* 1997; 419:112–116. [PubMed: 9426231]
- Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P. Vinblastine and sulfapyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. *Br J Cancer.* 2000; 83:375–383. [PubMed: 10917554]
- Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. *J Clin Invest.* 1998; 101:1310–1319. [PubMed: 9525973]
- Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. *Biochem Biophys Res Commun.* 1995; 208:345–352. [PubMed: 7887949]
- Germann UA, Pastan I, Gottesman MM. P-glycoproteins: mediators of multidrug resistance. *Semin Cell Biol.* 1993; 4:63–76. [PubMed: 8095827]
- Gimenez F, Fernandez C, Mabondzo A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. *J Acquir Immune Defic Syndr.* 2004; 36:649–658. [PubMed: 15167283]
- Gupta A, Zhang Y, Unadkat JD, Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). *J Pharmacol Exp Ther.* 2004; 310:334–341. [PubMed: 15007102]
- Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. *Biochim Biophys Acta.* 1999; 1461:359–376. [PubMed: 10581367]
- Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. *Aids.* 2002; 16:2295–2301. [PubMed: 12441801]
- Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. *Mol Pharmacol.* 2001; 59:806–813. [PubMed: 11259625]
- Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. *J Biol Chem.* 1993; 268:14991–14997. [PubMed: 8100817]

- Hurst M, Faulds D. Lopinavir. *Drugs*. 2000; 60:1371–1379. discussion 1380–1371. [PubMed: 11152017]
- Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. *Cancer Res*. 1993; 53:4595–4602. [PubMed: 8402633]
- Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. *J Natl Cancer Inst*. 2000; 92:1651–1656. [PubMed: 11036110]
- Katragadda S, Budda B, Anand BS, Mitra AK. Role of efflux pumps and metabolising enzymes in drug delivery. *Expert Opin Drug Deliv*. 2005; 2:683–705. [PubMed: 16296794]
- Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. *Proc Natl Acad Sci U S A*. 1995; 92:2484–2488. [PubMed: 7708670]
- Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. *J Clin Invest*. 1998; 101:289–294. [PubMed: 9435299]
- Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. *Proc Natl Acad Sci U S A*. 1999; 96:6914–6919. [PubMed: 10359813]
- Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. *Oncogene*. 2003; 22:7537–7552. [PubMed: 14576857]
- Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. *Drug Metab Dispos*. 1999; 27:902–908. [PubMed: 10421617]
- Kumar GN, Jayanti VK, Johnson MK, Uchic J, Thomas S, Lee RD, Grabowski BA, Sham HL, Kempf DJ, Denissen JF, Marsh KC, Sun E, Roberts SA. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with zidovudine in rats, dogs, and humans. *Pharm Res*. 2004; 21:1622–1630. [PubMed: 15497688]
- Lee BD, Li Z, French KJ, Zhuang Y, Xia Z, Smith CD. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. *J Med Chem*. 2004; 47:1413–1422. [PubMed: 14998330]
- Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). *J Cell Sci*. 2000; 113 (Pt 11):2011–2021. [PubMed: 10806112]
- Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. *Cell Mol Life Sci*. 2001; 58:931–959. [PubMed: 11497241]
- Miller JL. FDA approves new protease inhibitor for HIV infection. *Am J Health Syst Pharm*. 2000; 57:1942. [PubMed: 11094645]
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983; 65:55–63. [PubMed: 6606682]
- Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. *Life Sci*. 2006; 78:2131–2145. [PubMed: 16442130]
- Patick AK, Mo H, Markowitz M, Appelt K, Wu B, Musick L, Kalish V, Kaldor S, Reich S, Ho D, Webber S. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. *Antimicrob Agents Chemother*. 1996; 40:292–297. [PubMed: 8834868]
- Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. *Pharm Res*. 1999; 16:1206–1212. [PubMed: 10468021]

- Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Krohn A, et al. Rational design of peptide-based HIV proteinase inhibitors. *Science*. 1990; 248:358–361. [PubMed: 2183354]
- Shukla S, Robey RW, Bates SE, Ambudkar SV. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. *Biochemistry*. 2006; 45:8940–8951. [PubMed: 16846237]
- Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. *J Clin Invest*. 1999; 104:1441–1447. [PubMed: 10562306]
- Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. *J Pharmacol Exp Ther*. 2001; 299:164–170. [PubMed: 11561076]
- Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. *Proc Natl Acad Sci U S A*. 1994; 91:4096–4100. [PubMed: 8171040]
- van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. *Br J Cancer*. 1997; 76:1181–1183. [PubMed: 9365166]
- van Aubel RA, van Kuijk MA, Koenderink JB, Deen PM, van Os CH, Russel FG. Adenosine triphosphate-dependent transport of anionic conjugates by the rabbit multidrug resistance-associated protein Mrp2 expressed in insect cells. *Mol Pharmacol*. 1998; 53:1062–1067. [PubMed: 9614209]
- Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. *Aids*. 2003; 17:1092–1094. [PubMed: 12700464]
- Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. *Adv Drug Deliv Rev*. 2001; 46:89–102. [PubMed: 11259835]
- Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. *J Pharm Sci*. 1998; 87:1322–1330. [PubMed: 9811484]
- Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. *Mol Carcinog*. 1995; 13:129–134. [PubMed: 7619215]
- Wallstab A, Koester M, Bohme M, Keppler D. Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. *Br J Cancer*. 1999; 79:1053–1060. [PubMed: 10098736]
- Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. *Proc Natl Acad Sci U S A*. 2000; 97:7476–7481. [PubMed: 10840050]
- Williams GC, Liu A, Knipp G, Sinko PJ. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). *Antimicrob Agents Chemother*. 2002; 46:3456–3462. [PubMed: 12384350]
- Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. *Adv Drug Deliv Rev*. 1999; 39:211–238. [PubMed: 10837775]
- Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. *Aids*. 2005; 19:1617–1625. [PubMed: 16184031]

Figure 1.
Structure of Lopinavir

Figure 2. Transport of [3H] Lopinavir across MDCKII-WT as compared to the transfected cell lines

Figure 2a. MDCKII-WT in the absence of any efflux inhibitors.

Figure 2b. MDCKII-WT in the presence of efflux inhibitors (P-gp 4008, MK-571 and FC).

Figure 2c. MDCKII-MDR1 in the absence of any efflux inhibitors.

Figure 2d. MDCKII-MDR1 in the presence of P-gp 4008, a specific P-gp efflux inhibitor.

Figure 2e. MDCKII-MRP2 in the absence of any efflux inhibitors.

Figure 2f. MDCKII-MRP2 in the presence of MK-571, a specific MRP family inhibitor.

Figure 3.
Intracellular accumulation of [3H] MX in MDCKII-Bcrp1 cells
Asterisk (*) represents significant difference from control ($p < 0.05$)

Table 1

[3H] Lopinavir permeabilities and the corresponding Efflux Ratios obtained across MDCKII-WT cells

	A-B Permeability * 10⁶ cm/sec	B-A Permeability * 10⁶ cm/sec	Efflux ratio
Control	4.31 ± 0.50	5.70 ± 0.49*	1.32
P4 (50µM)	5.67 ± 0.47	6.28 ± 0.61	1.10
MK571 (100µM)	5.29 ± 0.48	5.72 ± 0.41	1.08
FC (10µM)	4.25 ± 0.30	5.39 ± 0.14*	1.27
MK571+P4+FC	5.26 ± 0.68	5.64 ± 0.34	1.07
ulb LVR 2.5µM	3.85 ± 0.52	5.02 ± 0.44	1.30
ulb LVR 5µM	4.05 ± 0.37	4.97 ± 0.18*	1.23
ulb LVR 10µM	4.96 ± 0.20	5.94 ± 0.20*	1.20
ulb LVR 25µM	5.21 ± 0.16	5.82 ± 0.52	1.12

Asterisk (*) mark on B-A permeability represents significant difference from A-B permeability (p <0.05)

Table 2

[3H] Lopinavir permeabilities and the corresponding Efflux Ratios obtained across MDCKII-MDR1 cells

	A-B Permeability * 10 ⁶ cm/sec	B-A Permeability * 10 ⁶ cm/sec	Efflux ratio
Control	1.32 ± 0.08	6.49 ± 0.76*	4.91
P4 (10µM)	3.20 ± 0.64	4.55 ± 0.30*	1.40
P4 (25µM)	3.60 ± 0.06	4.26 ± 0.23*	1.18
P4 (50µM)	4.60 ± 0.15	4.78 ± 0.11	1.03
GF (0.5µM)	4.61 ± 0.59	6.70 ± 0.51*	1.46
GF (1µM)	5.64 ± 0.39	7.28 ± 0.39*	1.25
GF (2µM)	6.32 ± 0.45	6.70 ± 0.37	1.06
ulb LVR 2.5µM	6.62 ± 0.44	8.75 ± 0.28*	1.32
ulb LVR 5µM	7.90 ± 0.41	9.37 ± 0.99*	1.18
ulb LVR 10µM	6.70 ± 0.31	7.85 ± 0.23*	1.12
ulb LVR 25µM	5.55 ± 0.18	6.06 ± 0.28*	1.09

Asterisk (*) mark on B-A permeability represents significant difference from A-B permeability (p <0.05)

Table 3

[3H] Lopinavir permeabilities and the corresponding Efflux Ratios obtained across MDCKII-MRP2 cells

	A-B Permeability * 10 ⁶ cm/sec	B-A Permeability * 10 ⁶ cm/sec	Efflux ratio
Control	2.32 ± 0.13	6.73 ± 0.45*	2.9
MK571(50μM)	3.08 ± 0.14	4.39 ± 0.23*	1.52
MK571(100μM)	4.89 ± 0.28	4.90 ± 0.28	1
MK571(200μM)	4.60 ± 0.15	4.78 ± 0.11	1.02
ulb LVR 1μM	3.45 ± 0.26	4.70 ± 0.24*	1.36
ulb LVR 2.5μM	4.46 ± 0.27	5.72 ± 0.25*	1.23
ulb LVR 5μM	4.49 ± 0.20	5.74 ± 0.20*	1.28
ulb LVR 10μM	4.50 ± 0.04	5.22 ± 0.31*	1.16
ulb LVR 25μM	1.88 ± 0.06	2.0 ± 0.32	1.09

Asterisk (*) mark on B-A permeability represents significant difference from A-B permeability (p <0.05)

Table 4

[3H] Lopinavir permeabilities and the corresponding Efflux Ratios obtained across MDCKII-MRP1 cells

	A-B Permeability * 10 ⁶ cm/sec	B-A Permeability * 10 ⁶ cm/sec	Efflux ratio
Control	4.54 ± 0.27	5.72 ± 0.25*	1.26
MK571(50μM)	4.71 ± 0.14	5.28 ± 0.23*	1.12
MK571(100μM)	5.09 ± 0.28	5.20 ± 0.43	1.02
MK571(200μM)	4.97 ± 0.52	5.05 ± 0.34	1.02
ulb LVR 2.5μM	3.32 ± 0.27	4.62 ± 0.25*	1.40
ulb LVR 5μM	3.45 ± 0.26	4.70 ± 0.24*	1.34
ulb LVR 10μM	4.99 ± 0.16	5.74 ± 0.26*	1.15
ulb LVR 25μM	4.49 ± 0.20	5.74 ± 0.20*	1.28

Asterisk (*) mark on B-A permeability represents significant difference from A-B permeability (p <0.05)

Table 5

[3H] Lopinavir and [3H] MX permeabilities and the corresponding Efflux Ratios obtained across MDCKII-Bcrp1 cells

	A-B Permeability * 10 ⁶ cm/sec	B-A Permeability * 10 ⁶ cm/sec	Efflux ratio
Control (3H MX)	3.03 ± 0.28	7.42 ± 0.60*	2.45
FC 1μM (3H MX)	5.06 ± 0.54	7.59 ± 0.79*	1.52
FC 5μM (3H MX)	6.00 ± 0.58	8.44 ± 0.72*	1.4
FC 10μM (3H MX)	9.11 ± 0.98	7.97 ± 0.72	1.14
Control (3H LVR)	7.64 ± 0.91	7.65 ± 0.63	1.08
FC+ MK571+P4 (3H LVR)	8.53 ± 0.28	8.42 ± 0.60	1.17

Asterisk (*) mark on B-A permeability represents significant difference from A-B permeability (p <0.05)